Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878
✍ Scribed by Scott Wadler; Beow Yeap; Steven Vogl; Paul Carbone
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 781 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
Following surgical debulking, most patients with International Federation of Gynecology and Obstetrics (FIGO) Stage 111 or IV carcinoma of the ovary receive treatment with combination chemotherapy. However, the optimal postsurgical therapy for ovarian carcinoma remains to be defined.
METHODS.
To define better the role of initial therapy with a cisplatin-based chemotherapy regimen, the Eastern Cooperative Oncology Group (ECOG) initiated a randomized, Phase 111 trial, EST 2878, comparing initial therapy with a single, orally administered alkylating agent, melphalan, versus a complex regimen employing cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD). Women who failed treatment with melphalan were crossed-over to treatment with CHAD minus the cyclophosphamide (HAD). Study endpoints included response to therapy, time to treatment failure, and overall survival.